From: Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
Endpoint positive | Endpoint negative | All patients | P values | ||
---|---|---|---|---|---|
All patients | 101 | 627 | 728 | ||
Male | 65 (64%) | 384 (61%) | 449 (62%) | 0.58 | |
Age 1 | 65 (57-77) | 64 (52-73) | 64 (53-73) | 0.048 | |
Race | 0.98 | ||||
White | 81 (80%) | 492 (78%) | 573 (79%) | ||
Black | 11 (11%) | 76 (12%) | 87 (12%) | ||
Other/Unknown | 9 (9%) | 59 (9%) | 68 (9%) | ||
Chronic comorbidities | |||||
Chronic kidney disease | 14 (14%) | 51 (8%) | 65 (9%) | 0.14 | |
Diabetes mellitus | 39 (39%) | 171 (27%) | 210 (29%) | 0.064 | |
Congestive heart failure | 23 (23%) | 99 (16%) | 122 (17%) | 0.17 | |
Coronary artery disease | 33 (33%) | 187 (30%) | 220 (30%) | 0.48 | |
Hypertension | 76 (75%) | 357 (57%) | 433 (59%) | 0.001 | |
Chronic obstructive pulmonary disease | 21 (21%) | 141 (22%) | 162 (22%) | 0.80 | |
Cancer | 25 (25%) | 163 (26%) | 188 (26%) | 0.53 | |
ICU type | 0.47 | ||||
Medical | 40 (40%) | 185 (30%) | 225 (31%) | ||
Surgical | 24 (24%) | 155 (25%) | 179 (25%) | ||
Combined ICU | 14 (14%) | 133 (21%) | 147 (20%) | ||
Cardiac surgery | 6 (6%) | 55 (9%) | 61 (8%) | ||
Neurologic | 5 (5%) | 34 (5%) | 39 (5%) | ||
Coronary care unit | 5 (5%) | 25 (4%) | 30 (4%) | ||
Trauma | 4 (4%) | 20 (3%) | 24 (3%) | ||
Other/Unknown | 3 (3%) | 20 (3%) | 23 (3%) | ||
Reason for ICU admission 2 | |||||
Respiratory | 47 (47%) | 263 (42%) | 310 (43%) | 0.39 | |
Surgery | 32 (32%) | 215 (34%) | 247 (34%) | 0.65 | |
Cardiovascular | 41 (41%) | 202 (32%) | 243 (33%) | 0.11 | |
Sepsis | 26 (26%) | 110 (18%) | 136 (19%) | 0.055 | |
Neurological | 8 (8%) | 62 (10%) | 70 (10%) | 0.72 | |
Trauma | 4 (4%) | 51 (8%) | 55 (8%) | 0.16 | |
Other | 21 (21%) | 105 (17%) | 126 (17%) | 0.32 | |
Enrollment serum creatinine 1,3 | 1.4 (0.9-1.8) | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | <0.001 | |
APACHE III 1,4 | 85 (59-106) | 67 (51-88) | 69 (51-91) | <0.001 |